Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent-Reference-Cited by-同舟云学术

Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent

Author:

Woolen Sean A.¹²,Shankar Prasad R.¹²,Gagnier Joel J.³⁴,MacEachern Mark P.⁵,Singer Lisa⁶,Davenport Matthew S.¹²⁷

Affiliation:

1. Department of Radiology, University of Michigan, Ann Arbor

2. Michigan Radiology Quality Collaborative, University of Michigan, Ann Arbor

3. Department of Orthopaedic Surgery, University of Michigan, Ann Arbor

4. Department of Epidemiology, University of Michigan, Ann Arbor

5. Taubman Health Sciences Library, University of Michigan, Ann Arbor

6. Dana-Farber Cancer Institute, Department of Radiation Oncology, Brigham and Women’s Hospital, Boston, Massachusetts

7. Department of Urology, Michigan Medicine, Ann Arbor

Publisher

American Medical Association (AMA)

Subject

Internal Medicine

Link

Reference37 articles.

2. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature.;Gibson;Arch Pathol Lab Med,2006

4. An updated study to determine association between gadolinium-based contrast agents and nephrogenic systemic fibrosis.;Zhang;PLoS One,2015

Cited by 161 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献